GHK-Cu dosage in the research literature: what was administered, to which model, by which route.

GHK-Cu dosage in the research literature is model-specific

GHK-Cu dosage in the research literature cannot be reduced to a single number because the compound was studied across a dose-response tendril that climbs roughly twelve orders of magnitude — from picomolar cell culture to milligram-per-millilitre topical scalp formulations. What follows describes what was administered to which model by which route. None of it is a human dosing recommendation; GHK-Cu has no FDA-approved drug product for any route, and no validated human pharmacokinetics.

The in-vitro anchor is precise: fibroblast collagen synthesis began at 10⁻¹² to 10⁻¹¹ M and peaked near 10⁻⁹ M ^[1]. Topical cosmetic and clinical formulations sit at roughly 0.05% to 2% (w/w) in creams, serums and gels. Rodent systemic studies span a wide band — for example mouse pulmonary models used intraperitoneal doses from 0.2 to 260 µg per unit, the cognition studies used 15 mg/kg intranasal ^[8][9], and rat behavioral studies ran from microgram-per-kilogram to roughly 0.5 mg/kg intraperitoneal ^[10]. The one controlled human hair trial used a topical 5-ALA + GHK complex at 50-100 mg/mL ^[4].

Routes Studied and Why the Route Matters

The route is not a detail in GHK-Cu research — it largely determines what the dose means. Topical application (creams, serums, liposomes, nano-lipid carriers, ionic-liquid microemulsions, wound dressings, nanofibers) is by far the most-studied and the only one with placebo-controlled human endpoints ^[3][4]. Intraperitoneal dosing carries the rodent systemic literature; intranasal delivery carries the cognition work ^[8][9]; oral gavage was used in a rodent colitis model; intravenous and subcutaneous routes appear in rodent pharmacokinetic studies; and intradermal microneedle or dermal-infusion delivery shows up in hair research.

The intranasal finding is the clearest illustration of why route governs interpretation. The mouse cognition benefits used 15 mg/kg intranasal GHK ^[8][9] — a route that delivers peptide toward the brain directly, bypassing systemic circulation. Reading those results as evidence of systemic or oral brain access would misstate what the studies showed. Topical results, similarly, speak to a dermal depot, not to plasma exposure ^[5].

The route also sets the metabolic fate. After intravenous dosing in rats, free GHK is rapidly converted to the dipeptide histidyl-lysine in plasma ^[15], so a systemic injection and a topical depot are not interchangeable ways of delivering "the same dose." Oral and intraperitoneal routes carry their own rodent literature — an oral-gavage colitis model and intraperitoneal pulmonary and behavioral studies among them — but none of these rodent systemic routes has a validated human pharmacokinetic counterpart, which is why this herbarium reports each dose strictly as what was given to which model.

Half-Life and Pharmacokinetics in the Research Record

No rigorous human pharmacokinetic half-life has been published for GHK-Cu. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases; a rat HPLC study documented rapid metabolism of GHK to the dipeptide histidyl-lysine (HK) after intravenous dosing, with detection limits of 50 ng/mL for GHK and 15 ng/mL for HK ^[15]. Secondary literature cites a short systemic elimination half-life on the order of 1-2 hours, with the copper-chelated complex more stable than free GHK; treat that figure as approximate, since it is not anchored to a validated human study.

Topical behavior is different and better quantified. Applied to skin, GHK-Cu forms a dermal copper depot — about 97 µg/cm² retained over 48 hours ^[5] — giving prolonged local availability rather than a short systemic pulse. In the same human penetration study the permeability coefficient was 2.43 x 10⁻⁴ cm/h and 136.2 µg/cm² of copper permeated over 48 hours ^[5], so the depot reflects retention rather than failure to cross. Injectable and systemic dosing protocols circulated in community contexts have no peer-reviewed human pharmacokinetic basis, which is the single most important gap in the dose record. That gap, and the tolerability signals that accompany it, are taken up directly in the GHK-Cu safety and tolerability questions.

Stability, Concentration and the Formulation Problem

The dose a study reports is only meaningful if the complex is intact, and GHK-Cu stability is governed by chemistry that any formulation has to respect. The complex carries a very high copper stability constant — log K about 16.4 — and is most stable near pH 5-6.5 at a 1:1 copper:peptide ratio, which is what limits pro-oxidant free-copper release. The blue-violet color of a reconstituted solution is the expected Cu(II) d-orbital absorption and signals an intact complex; a shift to brown or green indicates oxidation or precipitation.

Incompatibility is a real-world dose variable. Strong reducing agents reduce Cu(II) and break the complex — ascorbic acid (vitamin C) below about pH 3.5 is the classic case — and AHAs, BHAs and other low-pH actives can destabilize it or compete for the copper. A serum that pairs GHK-Cu with a low-pH vitamin C can therefore deliver less intact peptide than its label concentration implies.

Delivery is the other half of the problem. Free GHK is highly hydrophilic (clogP -2.24), which limits passive stratum-corneum penetration, and a 2025 review names this as the central topical challenge ^[13]. Enhancement strategies improve on the native molecule: palmitoylation (Pal-GHK, clogP about 1.14), liposomal encapsulation, ionic-liquid microemulsions, and microneedle pretreatment, which moved roughly 134 nmol of GHK across skin where intact skin passed essentially none ^[13]. Roughly 100 nm liposomal carriers reached 31.7% encapsulation efficiency, stayed stable for 4 weeks at room temperature, and produced 48.9% elastase inhibition in human epidermal cells without cytotoxicity ^[14]. Across these systems the concentration that matters is the intact GHK-Cu delivered to the dermis, not the percentage on the jar.